Informational research — not investment advice. Generated in part by AI and may contain errors; not a personal recommendation, solicitation, or offer. ReasyPort is not an authorised or regulated investment firm. Market data may be delayed or inaccurate. Capital is at risk and past performance does not guarantee future results — do your own research and consult a licensed adviser.
Full disclaimerReasyPort View: Cautious Watchlist — Cash Conversion Proof Required
Agilent Technologies is not just a laboratory-instrument vendor; it is a workflow-embedded analytical and clinical laboratory platform where instruments seed a recurring stream of services, consumables, software and automation. The business quality is real, but at $127.06 as of the 18 June 2026 close the stock stands about 24% above the selected fair value of $102.09, leaving owners to prove that fiscal 2026 non-GAAP EPS guidance becomes post-capex cash while Agilent funds the approximately $950m pending Biocare acquisition and the September 2026 note maturity without weakening per-share compounding.
The DCF framework uses a 9.25% WACC and 3.0% terminal growth. The conservative downside marker is $89.90, about 29% below the price, and the upside marker is $136.29, about 7% above the price. That means the market is not above the whole underwritten range, but it is already paying for a meaningful step-up from the selected case; the owner is buying execution proof, not a cheap reset.
The key macro issue is not life-science cyclicality in isolation, but whether Agilent’s instrument placements convert into recurring CrossLab economics and post-capex cash: if lab budgets keep funding placements and pull-through, fiscal 2026 growth can support Biocare, debt maturity and shareholder returns; if placements soften and cost recovery lags, guided EPS becomes less defensible and the valuation should stay anchored to cash-conversion proof.
Agilent reported fiscal Q2 2026 revenue of $1.835bn, up 10.0% reported and 6.3% core year over year. GAAP operating margin was 21.7%, non-GAAP operating margin was 26.4%, GAAP net income was $339m, GAAP diluted EPS was $1.20, and non-GAAP EPS was $1.49, up 14% year over year. Management raised fiscal 2026 guidance to revenue of $7.39bn-$7.49bn, 4.5%-6.0% core growth, non-GAAP operating-margin expansion of about 85 bps at the midpoint of core revenue growth, and non-GAAP EPS of $6.00-$6.10; Q3 fiscal 2026 guidance is revenue of $1.83bn-$1.85bn, reported growth of 5.0%-6.5%, core growth of 4.4%-5.9%, and non-GAAP EPS of $1.48-$1.50.
The cash bridge is less generous than the EPS bridge. For the first six months of fiscal 2026, operating cash flow was $545m versus $652m a year earlier; PP&E capex was $169m versus $211m; strict post-capex cash was therefore $376m. Dividends of $144m and buybacks of $217m consumed $361m, leaving only about $15m before acquisitions, debt maturities and other claims. One half-year is not a full-year run-rate, but it is exactly why the cash-conversion proof matters.
Create a free account to unlock the rest of this report and access all published research.